Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 34Lung Neoplasms 11Brain Neoplasms 2Radiation Pneumonitis 1Non-small Cell Lung Cancer Metastatic 1Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor 1NSCLC 1Meningeal Carcinomatosis 1Liver Diseases 1Digestive System Diseases 1Carcinoma 1Aumolertinib 1Advanced Non-small Cell Lung Cancer 1Adenocarcinoma 1

Interventions

nintedanib 2durvalumab 2Radiotherapy 2tislelizumab 1sugemalimab 1sintilimab 1pembrolizumab 1camrelizumab 1aumolertinib 1atezolizumab 1Tomography, Emission-Computed, Single-Photon 1Surveys and Questionnaires 1Respiratory Function Tests 1Prednisone 1Nivolumab 1Immunotherapy 1Immunoglobulin G 1Enalapril 1Disulfides 1Dexamethasone 1Cisplatin 1Breath Holding 1Adrenal Cortex Hormones 1Adjuvants, Immunologic 1Acetylcysteine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Radiation Pneumonitis × aumolertinib × Thoracic × Clear all
NCT04636593 2021-01-12

A Phase 2 Trial of Almonertinib With Concurrent Radiotherapy in The Treatment of Local Advanced EGFR-mutant NSCLC

First People's Hospital of Hangzhou

Phase 2 Unknown
43 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Radiation Pneumonitis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡